FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2135395655> ?p ?o ?g. }

• W2135395655 endingPage "412" @default.
• W2135395655 startingPage "401" @default.
• W2135395655 abstract "Cytomegalovirus-caused diseases are preventable. We believe that both neutralising antibodies and cell-mediated immunity are necessary for prevention. Of the CMV proteins, gB and pp65 are the minimum requirements in a vaccine to induced neutralising antibodies and cytotoxic T-lymphocyte (CTL) responses. Immunisation with additional proteins, e.g., gH, gN for neutralising antibodies and IE1exon 4 and pp150 for CTL responses, would strengthen protective immune responses. Approaches to development of a safe and effective cytomegalovirus (CMV) vaccine for the prevention of CMV diseases include: a) a live attenuated vaccine (Towne strain); b) recombinant constructs of the attenuated Towne and the virulent Toledo CMV strains; c) subunit glycoprotein B (gB) adjuvanted with MF59 to induce neutralising antibodies; d) phosphoprotein 65 (pp65) peptide-based vaccines to induce (CTL) for use in therapeutic vaccination; e) canarypox-CMV recombinants, e.g., ALVAC-CMV(gB) and ALVAC-CMV (pp65) to induce neutralising antibodies and CTL responses, respectively; f) DNA plasmids containing the genes for gB and pp65; g) dense bodies containing the key antigens. The attenuated Towne strain, gB/MF59, ALVAC-CMV(gB) and ALVAC-CMV(pp65) approaches have already been tested in clinical trials. The Towne vaccine induced neutralising antibodies and cell-mediated immunity (including CTLs) mitigated CMV disease in seronegative renal transplant recipients and protected against a low-dose virulent CMV challenge in normal volunteers but did not prevent infection in mothers of children excreting CMV. Immunisation with gB/MF59 resulted in high levels of neutralising antibodies in seronegative subjects. ALVAC-CMV(gB) did not induce neutralising antibodies but primed the immune system to a Towne strain challenge, while ALVAC-CMV(pp65) induced long-lasting CTL responses in all originally seronegative volunteers, with CTL precursor frequency similar to naturally seropositive individuals. These results suggest that CMV diseases can be prevented or attenuated and that a vaccine combining ALVAC-CMV(pp65) with gB/MF59 may induce sufficient CTLs and neutralising antibodies to protect against CMV diseases. Meanwhile, other approaches such as DNA peptide and dense body vaccines, should enter Phase I trials. All candidate vaccines will have to demonstrate that immunogenicity provides protection. Combined vaccines containing canarypox (ALVAC) vectors to express CMV-pp65 to induce CTLs and of subunit gB, given together with an appropriate adjuvant to induce neutralising antibodies, should be tested in a target population for the prevention of CMV infection and disease." @default.
• W2135395655 created "2016-06-24" @default.
• W2135395655 creator A5051106762 @default.
• W2135395655 creator A5079512093 @default.
• W2135395655 date "2001-05-01" @default.
• W2135395655 modified "2023-09-28" @default.
• W2135395655 title "Development of a cytomegalovirus vaccine: lessons from recent clinical trials" @default.
• W2135395655 cites W1568041502 @default.
• W2135395655 cites W1638089104 @default.
• W2135395655 cites W1916620382 @default.
• W2135395655 cites W1968226134 @default.
• W2135395655 cites W1973361064 @default.
• W2135395655 cites W1974933384 @default.
• W2135395655 cites W1978037344 @default.
• W2135395655 cites W1985063839 @default.
• W2135395655 cites W1990626907 @default.
• W2135395655 cites W1994667326 @default.
• W2135395655 cites W1996083596 @default.
• W2135395655 cites W1998632067 @default.
• W2135395655 cites W2015400860 @default.
• W2135395655 cites W2016777908 @default.
• W2135395655 cites W2032572780 @default.
• W2135395655 cites W2036123754 @default.
• W2135395655 cites W2045565162 @default.
• W2135395655 cites W2053161235 @default.
• W2135395655 cites W2056683115 @default.
• W2135395655 cites W2058479453 @default.
• W2135395655 cites W2060448757 @default.
• W2135395655 cites W2060907413 @default.
• W2135395655 cites W2064975687 @default.
• W2135395655 cites W2065113855 @default.
• W2135395655 cites W2066964567 @default.
• W2135395655 cites W2073207520 @default.
• W2135395655 cites W2079647175 @default.
• W2135395655 cites W2081095625 @default.
• W2135395655 cites W2088663340 @default.
• W2135395655 cites W2090359320 @default.
• W2135395655 cites W2091978710 @default.
• W2135395655 cites W2102254194 @default.
• W2135395655 cites W2102850108 @default.
• W2135395655 cites W2103589467 @default.
• W2135395655 cites W2143682490 @default.
• W2135395655 cites W2144512751 @default.
• W2135395655 cites W2153568939 @default.
• W2135395655 cites W2153774223 @default.
• W2135395655 cites W2156604614 @default.
• W2135395655 cites W2162363490 @default.
• W2135395655 cites W2163183562 @default.
• W2135395655 cites W2166478118 @default.
• W2135395655 cites W2166789299 @default.
• W2135395655 cites W2315098267 @default.
• W2135395655 cites W2315326052 @default.
• W2135395655 cites W2340978599 @default.
• W2135395655 cites W2616662114 @default.
• W2135395655 cites W40694895 @default.
• W2135395655 cites W4241169271 @default.
• W2135395655 doi "https://doi.org/10.1517/14712598.1.3.401" @default.
• W2135395655 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11727514" @default.
• W2135395655 hasPublicationYear "2001" @default.
• W2135395655 type Work @default.
• W2135395655 sameAs 2135395655 @default.
• W2135395655 citedByCount "67" @default.
• W2135395655 countsByYear W21353956552012 @default.
• W2135395655 countsByYear W21353956552013 @default.
• W2135395655 countsByYear W21353956552014 @default.
• W2135395655 countsByYear W21353956552016 @default.
• W2135395655 countsByYear W21353956552017 @default.
• W2135395655 countsByYear W21353956552018 @default.
• W2135395655 countsByYear W21353956552020 @default.
• W2135395655 countsByYear W21353956552021 @default.
• W2135395655 crossrefType "journal-article" @default.
• W2135395655 hasAuthorship W2135395655A5051106762 @default.
• W2135395655 hasAuthorship W2135395655A5079512093 @default.
• W2135395655 hasConcept C147483822 @default.
• W2135395655 hasConcept C147969180 @default.
• W2135395655 hasConcept C154317977 @default.
• W2135395655 hasConcept C159047783 @default.
• W2135395655 hasConcept C159654299 @default.
• W2135395655 hasConcept C167508917 @default.
• W2135395655 hasConcept C167672396 @default.
• W2135395655 hasConcept C202751555 @default.
• W2135395655 hasConcept C203014093 @default.
• W2135395655 hasConcept C22070199 @default.
• W2135395655 hasConcept C2779341262 @default.
• W2135395655 hasConcept C2780801004 @default.
• W2135395655 hasConcept C2780868878 @default.
• W2135395655 hasConcept C55493867 @default.
• W2135395655 hasConcept C71924100 @default.
• W2135395655 hasConcept C86803240 @default.
• W2135395655 hasConcept C8891405 @default.
• W2135395655 hasConceptScore W2135395655C147483822 @default.
• W2135395655 hasConceptScore W2135395655C147969180 @default.
• W2135395655 hasConceptScore W2135395655C154317977 @default.
• W2135395655 hasConceptScore W2135395655C159047783 @default.
• W2135395655 hasConceptScore W2135395655C159654299 @default.
• W2135395655 hasConceptScore W2135395655C167508917 @default.
• W2135395655 hasConceptScore W2135395655C167672396 @default.
• W2135395655 hasConceptScore W2135395655C202751555 @default.

• next